Loading data for SER — first visit, this takes a few seconds.
Serina Therapeutics, Inc. (SER)
NYSE American: SER
· 实时价格 · USD
2.50
-0.07 (-2.72%)
收盘价： Sep 11, 2026, 8:00 PM
股价、关键数字和最新消息，都在这一页。
Serina Therapeutics, Inc.（SER）股价、分析与数据
暂无数据
| 买价 | 2.38 |
| 市值 | 56.4M |
| 营收（TTM） | 0 |
| 净利润（TTM） | -23.9M |
| 0.09 | |
| -1.66 | |
| n/a | |
| -2.11 | |
| 市净率（TTM） | 3.01 |
| 市销率（TTM） | 0.00 |
| 财报日期 | n/a |
| 卖价 | 2.48 |
| 成交量 | 68,818 |
| 20日均量 | 79,800 |
| 开盘价 | 2.55 |
| 前收盘价 | 2.57 |
| 日内区间 | 2.36 - 2.58 |
| 52周区间 | 1.22 - 5.83 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early ...
公司完整简介财报意外
Serina Therapeutics 已于 Aug 13, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -0.52 低于预期 -0.17, ， 21.21% 同比增长.
